Novel Therapeutic Approaches for Inclusion Body Myositis

Thomas E. Lloyd


Curr Opin Rheumatol. 2010;22(6):658-664. 

In This Article


Novel therapies to accelerate muscle regeneration and to prevent degeneration are on the horizon. Myostatin inhibition to accelerate muscle regeneration is a promising therapeutic approach for many muscle diseases including myositis, and clinical trials are underway. We are just beginning to understand the pathogenesis of IBM, and findings of defects in autophagy and accumulations of TDP-43 suggest that these may be new therapeutic targets. One limitation to clinical trials for IBM is a clear biomarker of disease, and future research should focus on identifying which of these new pathologic features correlate with disease activity.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: